Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Moots Digital Joint Venture

May Build On Collaboration With MedPeer Digital Services Provider

Executive Summary

Nichi-Iko is exploring the possibility of a joint venture with digital services provider MedPeer, building on a collaboration that the Japanese generics firm believes will represent a “new generic drugs business model.”

You may also be interested in...



Nichi-Iko And Eisai Expand Alliance To China

Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

NDMA In Ranitidine Risks Rerun Of Sartans Crisis

Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.

Gene Techno Collaborates With Kishi Kasei On Aflibercept

Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel